Among 42,910 matched pairs of patients with MASLD and type 2 diabetes in the TriNetX database, GLP-1 receptor agonists were associated with a 13% lower risk of a composite cardiovascular outcome versus sulfonylureas (HR 0.87, 95% CI 0.84-0.91). The signal disappeared in 90-day and 180-day landmark analyses. In Western diet-fed mice, GLP-1 treatment improved selected cardiac function indices, reduced cardiomyocyte hypertrophy, and lowered CTGF, TGF-β1 and vimentin expression, though the fibrosis reduction missed significance (P = 0.28).
The headline hazard ratio fits what larger trials show for GLP-1 drugs in type 2 diabetes, but the weak spots matter more here. Sulfonylureas are an unflattering comparator, since they carry their own cardiovascular and hypoglycemia concerns, which can inflate the apparent benefit. Loss of significance in landmark analyses points to immortal-time or early-exposure bias, so the observational estimate should be read cautiously. TriNetX data also rely on electronic records, with limited detail on liver fibrosis stage, BMI trajectory and adherence. The mouse work offers plausible mechanisms, namely less hypertrophy and dampened profibrotic signaling, but animal findings cannot confirm the same pathway operates in people, and the fibrosis endpoint was null. Treat this as confirmatory and hypothesis-generating rather than practice-changing. Adults with fatty liver and diabetes already have strong reasons to discuss GLP-1 therapy with their doctor for glycemic and weight control, and this adds modest, imperfect support for cardiac benefit. Randomized evidence in MASLD-specific populations is still needed.